Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series

Nivolumab is an anti‐PD‐1 blocking monoclonal antibody approved for the treatment of non‐small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed the clinical...

詳細記述

保存先:
書誌詳細
出版年:Thorac Cancer
主要な著者: Kanazu, Masaki, Edahiro, Ryuya, Krebe, Hiroyuki, Nishida, Kohei, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons Australia, Ltd 2018
主題:
Case Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275832/
https://ncbi.nlm.nih.gov/pubmed/30328672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12894
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料